Since it is reported that expression of NY-ESO-1 was seen in 70–80% of synovial sarcomas, but not in any normal adult tissues except the testis [111,112,113], NY-ESO-1 has been considered as an attractive target of immune-based therapy. The gene discussed is CTAG1B; the disease is synovial sarcoma.